Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | FCER2 | P06734 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
| ▸ | PTGFR | P43088 | 1/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350753 | 1.00 | KIF11 (0.52) | KIF11MMP1FCER2MAPTHPGD | |
| SCHEMBL7442311 | 0.81 | NPC1 (0.46) | KIF11MMP1FCER2MAPTHPGD | |
| SCHEMBL7442301 | 0.81 | NPC1 (0.46) | KIF11MMP1FCER2MAPTHPGD | |
| SCHEMBL4573064 | 0.76 | MMP1 (0.50) | MMP1FCER2MAPTHPGDCYP2C19 | |
| SCHEMBL4573057 | 0.76 | MMP1 (0.50) | MMP1FCER2MAPTHPGDCYP2C19 | |
| SCHEMBL6282249 | 0.75 | PTGER1 (0.51) | MMP1FCER2MAPTHPGDCYP2C19 | |
| SCHEMBL20393464 | 0.75 | MMP1 (0.48) | MMP1FCER2MAPTHPGDNPC1 | |
| SCHEMBL7247505 | 0.75 | MAOA (0.50) | MMP1FCER2MAPTHPGDNPC1 | |
| SCHEMBL11386082 | 0.74 | KMT2A (0.58) | KIF11MAPTHPGDCYP2C19NPC1 | |
| SCHEMBL11386091 | 0.74 | KMT2A (0.58) | KIF11MAPTHPGDCYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105264064-B | O-phosphoserine export proteins and methods of producing O-phosphoserine using the same | CJ第一制糖株式会社 | 2020-08-18 | — | — | CN | claimed |
| EP-3348567-B1 | NOVEL O-PHOSPHOSERINE EFFLUX PROTEIN VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE AND DERIVATIVE THEREOF USING SAME | CJ CHEILJEDANG CORP (KR) | 2020-08-05 | — | — | EP | claimed |
| EP-3181685-B1 | O-PHOSPHOSERINE PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-PHOSPHOSERINE OR L-CYSTEINE USING SAME | CJ CHEILJEDANG CORP (KR) | 2019-08-14 | — | — | EP | claimed |
| US-12529082-B2 | O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivatives thereof using the same | CJ CHEILJEDANG CORPORATION (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250376493-A1 | NOVEL YhhS VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATE OF CYSTEINE USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2025-12-11 | — | — | US | disclosed |
| US-20250075221-A1 | O-PHOSPHOSERINE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCING O-PHOSPHOSERINE OR L-CYSTEINE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2025-03-06 | — | — | US | disclosed |
| CN-118786220-A | Microorganism producing O-phosphoserine and method for producing O-phosphoserine or L-cysteine using the same | CJ第一制糖株式会社 | 2024-10-15 | — | — | CN | disclosed |
| US-20240294955-A1 | RECOMBINANT MICROORGANISM IN WHICH EXPRESSION OF NADH:QUINONE OXIDOREDUCTASE IS CONTROLLED, AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATIVE THEREOF BY USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2024-09-05 | — | — | US | disclosed |
| US-20240287559-A1 | NOVEL MdtH VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATIVE OF CYSTEINE USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2024-08-29 | — | — | US | disclosed |
| EP-4368632-A1 | NOVEL YHHS VARIANT AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATE OF CYSTEINE USING SAME | CJ CheilJedang Corporation (KR) | 2024-05-15 | — | — | EP | disclosed |
| CN-117980321-A | Novel MdtH variants and methods of using the same to produce O-phosphoserine, cysteine, and cysteine derivatives | CJ第一制糖株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-20150218538-A1 | Methods and Compositions for Modulating G-Alpha-Q Signaling | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-8445678-B2 | 2-quinoxalinol salen compounds and uses thereof | AUBURN UNIVERSITY (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2013029648-A1 | NEW AMINOACID COMPOUNDS FOR TREATING TUMOURS AND AUTOIMMUNE DISEASES | ARKE' ORGANICS S.R.L. (IT) | 2013-03-07 | — | — | WO | disclosed |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | AUBURN UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | AUBURN UNIVERSITY (US) | 2009-11-19 | — | — | US | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286968-A1 | 2-Quinoxalinol Salen Compounds and Uses Thereof | NQO1, NQO2, SQOR | KIF11 3663/4885MMP1 4818/4885FCER2 4512/4885 |
| US-20120028362-A1 | 2-QUINOXALINOL SALEN COMPOUNDS AND USES THEREOF | NQO1, NQO2, SQOR | KIF11 3663/4885MMP1 4818/4885FCER2 4512/4885 |
| US-12529082-B2 | O-phosphoserine export protein variant and method for producing O-phosphoserine, cysteine, and derivatives thereof using the same | PSPH, PHAX, MARS1 | KIF11 716/4885MMP1 2371/4885FCER2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.